瑞普生物：10月13日召开董事会会议

Group 1 - The core point of the article is that Reap Bio (SZ 300119) held a temporary board meeting on October 13, 2025, to discuss investment proposals with professional investment institutions [1] - For the year 2024, Reap Bio's revenue composition is as follows: 43.12% from veterinary biological products, 33.86% from veterinary drugs, 20.63% from pet supply chains, and 2.38% from other sources [1] - As of the report date, Reap Bio has a market capitalization of 10.2 billion yuan [1]